BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Alnylam’s pipeline is built on small interfering RNA (siRNA), synthetic molecules that silence specific mRNAs. After nearly 15 years of investment in the field, Alnylam is now nearing the moment ...

potentially bringing it into competition with biotech heavyweights such as Alnylam, something that Mortazavi focused on during his long time at the helm of Silence Therapeutics. The company has ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post to the agency’s website. Published first on ...

Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64.

Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended December 2024. While this widely-known ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...